z-logo
Premium
Single‐Dose Pharmacokinetics of Atrasentan, an Endothelin‐A Receptor Antagonist
Author(s) -
Samara Emil,
Dutta Sandeep,
Cao Guoliang,
Granneman G. R.,
Dordal Margaret S.,
MD R. J. Padley
Publication year - 2001
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/00912700122010258
Subject(s) - pharmacokinetics , medicine , pharmacology , volume of distribution , placebo , distribution (mathematics) , mathematics , mathematical analysis , alternative medicine , pathology
The pharmacokinetics of 1, 10, 23.25, and 139.5 mg doses of atrasentan was assessed in a placebo‐controlled, double‐blind, single oral dose study in 24 healthy male subjects. Atrasentan was well tolerated. Atrasentan pharmacokinetics was linear in the 1 to 23.25 mg dose range, with some dose dependency in the highest dose group. Harmonic mean terminal half‐life was similar across all dose groups (20–25 h). Apparent oral clearance was low (12 L/h) for the highest dose group compared with the other three dose groups (21–27 L/h). The apparent volume of distribution was large (∼6 L/kg), consistent with extensive tissue distribution.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom